Thursday, February 4, 2021

Advertising

Home Business News Noxopharm COVID-19 treatment trial advances to the final stage

Noxopharm COVID-19 treatment trial advances to the final stage

A trial of medtech Noxopharm’s (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company’s investors.

Shares in the Sydney-based company were up nearly 3 per cent this morning after Noxopharm’s independent safety committee cleared a trial of its drug Veyonda for the treatment of COVID-19 complications to move to the next stage.

As such, a final cohort of COVID-19 infected recipients in the US will receive a dosage of Veyonda, an experimental anti-cancer drug.

“The company regards this as a highly encouraging outcome given the advanced nature of COVID-19 disease in these study patients, in particular suffering serious lung dysfunction,” says…



Click here to view the original article.

- Advertisment -
- Advertisment -

Most Popular

Weather News – Dangerous storms to hit southeastern Australia on Friday

Dangerous storms to hit southeastern Australia on Friday Ben Domensino, Thursday February 4, 2021 - 16:31 EDT Heavy rain, damaging...

Underemployment and wages stagnation threatens COVID recovery, warns economist

A leading economist is warning labour market slack will push your take-home pay lower over the next two years and that could threaten...

Taylor Swift sued by theme park Evermore

Taylor Swift has been sued by a theme park for trademark infringement over the title of her latest album Evermore.The owners of Evermore,...

ASX 200 falls 0.9%, Nick Scali reports, Vulcan jumps on Thursday 4 February 2021

The S&P/ASX 200 Index (ASX: XJO) fell 0.9% today to 6,766 points. Here are some of the highlights from today:The...

You might also like ...

Diageo North America Establishes Innovative Program With HBCUs to Develop Future Leaders and Help Sh…
PulteGroup Announces Quarterly Cash Dividend of $0.14 Per Share